Premium
Csl Ltd (QX) (CSLLY)
USOTC
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.
CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for Neurological Disorders PR Newswire KING OF PRUSSIA, Pa...
CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO, June 24, 2015 - Data supports prolonged dosing...
CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24, 2015 Data Presented during Late Breaking Session at...
Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how value of biopharmaceutical technologies is assessed...
CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More than 20 abstracts focusing on investigational and...
Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) PR Newswire KING OF...
National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring Recognized for its Longstanding Commitment to Delivering Innovative Products and Programs that...
Science, Information, And Technology Driving Evolution Of Global Healthcare Industry serves critical role in advancing healthcare and improving the well-being of patients, says CSL CEO Paul...
CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science PR Newswire MARBURG, Germany, April 23, 2015 CSL Behring Professor Heimburger Award Provides 100,000 Euros in...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.309 | -1.30580078807 | 100.245 | 101.08 | 98.16 | 12996 | 99.50168731 | DR |
| 4 | -7.174 | -6.76090849119 | 106.11 | 108.5 | 95.05 | 19280 | 101.24301063 | DR |
| 12 | -2.574 | -2.53571076741 | 101.51 | 109 | 95.05 | 19673 | 101.73549939 | DR |
| 26 | 3.225 | 3.36951865512 | 95.711 | 109 | 85.96 | 27989 | 95.62890595 | DR |
| 52 | 18.1595 | 22.4811671711 | 80.7765 | 109 | 71.51 | 46150 | 88.30342151 | DR |
| 156 | -11.914 | -10.747857465 | 110.85 | 117.24 | 71.51 | 63732 | 92.79310181 | DR |
| 260 | 19.532 | 24.5982570148 | 79.404 | 117.98 | 71.51 | 56651 | 95.87446334 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
